In conclusion, we here identified an HLA class II neoantigen encoded by the well-known DNMT3A-R882H hotspot mutation that may become an important target for immunotherapeutic strategies to treat HLA-DQB1*06:02 or -DQB1*06:03 positive patients with AML. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.